Published on 9 Nov 2023 on Benzinga via Yahoo Finance
These Biotech Stocks Could Double Your Money, According To Analysts
The biotech industry has been in the limelight since the COVID-19 pandemic, with public and private sectors pouring in funds to bolster innovation and the development of relevant drugs.
Approximately 63% of public biotech firms reported revenue growth in 2021. Emerging biotech companies, which have annual revenue below $500 million, recorded a median 40% annual revenue growth rate, outpacing industry giants, which reported a lower 35% average annual revenue growth rate.